Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023

Business Wire October 3, 2023

Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders

Business Wire October 2, 2023

CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment

Business Wire September 19, 2023

Kite's Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma

Business Wire September 18, 2023

Gilead's Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Business Wire September 10, 2023

Gilead Prices $2 Billion of Senior Unsecured Notes

Business Wire September 7, 2023

Gilead Sciences: How One School Has Transformed Education for First-Generation Students

ACCESS Newswire September 6, 2023

Gilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South

ACCESS Newswire August 30, 2023

FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment

Business Wire August 24, 2023

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire August 23, 2023

How Gilead's Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines

ACCESS Newswire August 23, 2023

Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML

Business Wire August 21, 2023

Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States

Business Wire August 18, 2023

Gilead's Focus on Ending the HIV Epidemic for Children Everywhere

ACCESS Newswire August 16, 2023

Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation

Business Wire August 15, 2023

Gilead Sciences: A Cut Above the Rest: Innovative Barbershop Program Educates Indigenous Men About HIV

ACCESS Newswire August 9, 2023

Gilead Sciences Announces Second Quarter 2023 Financial Results

Business Wire August 3, 2023

Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities

ACCESS Newswire August 2, 2023

European Commission Approves Gilead's Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer

Business Wire July 27, 2023

Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV

Business Wire July 24, 2023